Amer Beitinjaneh, MD, MSc, MPH, FACP, on Treating EBV+ PTLD With Tab-cel


The associate professor of medicine at Sylvester Comprehensive Cancer Center discussed updated data from the phase 3 ALLELE study.

“For patients with EBV-positive Post-Transplant Lymphoproliferative Disorder who failed rituximab-based therapy, the outcome is usually very dismal... Median overall survival is often less than 4 months and there are currently no approved treatments indicated for those patients. So initially, we will use immune suppression and rituximab-based therapy, but once you fail, you will pretty much have no options.”

Tabelecleucel (tab-cel; Atara Biotherapeutics), an allogeneic Epstein–Barr virus (EBV)-specific T-cell immunotherapy, produced clinically meaningful outcomes and demonstrated a promising safety profile in patients with EBV-positive post-transplant lymphoproliferative disease (EBV+ PTLD) treated in the phase 3 ALLELE clinical trial (NCT03394365). Updated data from the trial were presented at the 2023 Tandem Meetings |Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR, held in Orlando, Florida, February 15-19, 2023, by Amer Beitinjaneh, MD, MSc, MPH, FACP, associate professor of medicine at Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami.

CGTLive spoke with Beitinjaneh about the updated results from the ALLELE study. He discussed the unmet need that tab-cel can help address in patients with EBV+ PTLD. Tab-cel is approved in the European Union in the same indication.

Beitinjaneh A, Baiocchi R, Choquet S, et al. New and updated results from a multicenter, open-label, global phase 3 (P3) study of tabelecleucel (Tab-cel) for Epstein–Barr virus-positive post-transplant lymphoproliferative disease (EBV+ PTLD) following allogeneic hematopoietic cell (HCT) or solid organ transplant (SOT) after failure of rituximab (R) or rituximab and chemotherapy (R+CT) (ALLELE). Presented at: 2023 Tandem Meetings, February 15-19, 2023; Orlando, Florida. Abstract #25.
Related Videos
David Suhy, PhD, the cofounder and chief scientific officer of Earli
Deepak L. Bhatt, MD, MPH, MBA, on Incorporating AI into Genetic Research for Cardiovascular Disease
Jeffrey Chamberlain, PhD, on Helping Progress Cell and Gene Therapy Development
Jonathan W. Weinsaft, MD, on Integrating Genetic Research into Cardiovascular Medicine
Jacques Galipeau, MD, on Highlights from ISCT 2024’s Presidential Plenary
Vanee Pho, PhD, the senior director of product management, cell and gene therapy, at Mission Bio
Michael Wang, MD, a professor in the Department of Lymphoma/Myeloma at MD Anderson Cancer Center
Robert J. Hopkin, MD, on Looking Deeper into Fabry Disease Biology
Steven W. Pipe, MD, on Confirming Efficacy, Safety of Hemgenix Gene Therapy in Hemophilia B Populations
Rawan Faramand, MD, an assistant professor at Moffit Cancer Center
© 2024 MJH Life Sciences

All rights reserved.